Personalized TB treatment using sputum tests
Part of Infections clinical trials.
This study tests whether using a detailed sputum test to guide treatment for drug-resistant tuberculosis (TB) leads to better outcomes. Participants' treatment is tailored based on the specific drug resistance found, which may help them recover faster and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tuberculosis (TB) that is resistant to rifampicin, a common TB medicine.
- You have just started TB treatment or haven't been on it for more than 7 days.
- You are 18 years or older.
- You are able to attend regular visits at the study site.
- You are not pregnant, breastfeeding, or planning to conceive within 6 months after treatment.
- You do not have any serious medical condition that could be worsened by participating.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This study tests rapid TB screening and lab-style diagnostic methods to see how well they find TB disease and TB that is resistant to rifampin (a key TB drug). It may help doctors diagnose TB faster and more accurately, especially in people at higher risk.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
Hear when a new Tuberculosis, Multidrug-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.